BofA raises Gilead Sciences stock price target on growth outlook
BofA Securities raised its price target on Gilead Sciences (GILD) to $164 from $162, maintaining a Buy rating. The stock is trading at $151.17. BofA projects strong Q3 sales for several Gilead drugs and expects growth in oncology and immunology pipelines. Gilead's Q2 2026 earnings beat expectations, with revenue of $7.8 billion. The company also announced collaborations with Assembly Biosciences and MacroGenics.
How this was made
The 30-second read
Why it matters
The analyst upgrade provides a fresh catalyst that could move the stock despite the earnings already being known.
Market read
Analyst price target upgrades can prompt short-term buying, especially when tied to optimistic sales forecasts.
What to watch
Potential headwinds from acquisition-related charges and regulatory scrutiny of new oncology drugs.
Background
The article recaps Gilead's recent Q2 results and BofA's upgraded price target, adding analyst perspective to previously reported earnings.
Ticker impact
BofA raised its price target on Gilead Sciences to $164 (and later $168) with a Buy rating, citing stronger sales forecasts and growth outlook.
likely upward pressure as investors price in the higher target and growth expectations
The new target reflects fresh sales guidance and a bullish outlook, which can attract buying interest.
Market effects
Positive signal for the broader biotech/HIV/oncology sector as BofA highlights Gilead's pipeline strength.
US biotech equities may see modest gains from the upgrade.
Limited to investors tracking US pharma stocks.
Counterpoint
The price target increase may be premature if upcoming earnings miss expectations or if competition intensifies.
Key entities
- companyGilead Sciences Inc.
US biotech firm focused on HIV, oncology, and liver disease.
- analystBofA Securities
Investment bank raising price target and maintaining Buy rating.
